Portola Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Portola Pharmaceuticals's estimated annual revenue is currently $24M per year.
- Portola Pharmaceuticals received $345.0M in venture funding in September 2017.
- Portola Pharmaceuticals's estimated revenue per employee is $55,684
- Portola Pharmaceuticals's total funding is $772M.
- Portola Pharmaceuticals has 431 Employees.
- Portola Pharmaceuticals grew their employee count by 23% last year.
- Portola Pharmaceuticals currently has 1 job openings.
|Mardi Dier||EVP & CFO|
|Lee Mermelstein||Executive Director, Manufacturing and Biosciences|
|Ernie Meyer||Executive Vice President and Chief Human Resources Officer|
|John Curnutte||Executive Vice President of Research & Development|
|Evan Susser||Senior Director, QA|
|Alpana Loomba||Director, Clinical Operations|
|Charlotte Furey||Director, Clinical Data Management|
|Ravi Kumar Monangi||Director, IT - (Enterprise Architecture, Security, Quality/Compliance)|
|Vikas Kawatra||Vice President of Information Technology|
|William Pretto||Director, Sales Operations|
What Is Portola Pharmaceuticals?
We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|ZO Skin Health||$55.5M||295||2%||N/A|
Portola Pharmaceuticals News
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced plans to offer, ...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing ...
Portola Pharmaceuticals (NASDAQ:PTLA) is down 4.8% after filing to offer $200M in common shares. The prospectus comes via Goldman ...
Portola Pharmaceuticals Funding
|2005-01-19||$21.0M||A||Sutter Hill Ventures, Prospect Ventures||Article|
|2005-11-09||$46.0M||B||Advanced Technology Ventures||Article|
|2006-10-18||$20.0M||Undisclosed||Hercules Technology Growth Cap||Article|
Portola Pharmaceuticals Executive Hires
|2008-06-25||Bill Lis||VP Biz Development/Commercial Operatio||Article|
|2017-11-07||John Lawrence||SVP Product Development & Chief Medical Officer||Article|
|2018-03-13||John Moriarty||EVP & General counsel||Article|
|2018-06-26||Glenn Brame||senior vice president of technical operations||Article|
|2018-08-10||Ernie Meyer||EVP & Chief Human Resources Officer||Article|
|2019-01-29||Sheldon Koenig||EVP & Chief Commercial Officer||Article|